Compare MasTec Inc (MTZ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Smith & Nephew plc — how do they compare? MasTec Inc trades at $240.68 (market cap $19.77B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: MasTec Inc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.85% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | SNN | |
|---|---|---|
Market Cap | $19.77B | $11.63B |
Sector | Technology | Health |
52-Week High | $437.51 | $38.53 |
52-Week Low | $189.18 | $27.80 |
Enterprise Value | $22.69B | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $246.18, up 3.79% today, with strong analyst support (88.9% buy ratings) and a consensus price target of $436.50. The stock shows bearish technical signals but benefits from record $21.4B backlog and AI infrastructure exposure. Recent Q2 2026 earnings missed expectations slightly, though revenue grew 23% year-over-year. The company raised its 2026 outlook, highlighting expanding data center capabilities and power delivery growth.
MTZ presents a growth opportunity driven by infrastructure demand and AI-linked projects, but faces risks from premium valuation (P/E 39.2), weak cash flow trends, and communications segment softness. Investors should weigh strong institutional interest against execution challenges in a competitive market.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
